Vallon Pharmaceuticals, Inc.

Informe acción NasdaqCM:VLON

Capitalización de mercado: US$5.4m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Vallon Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

-25.1%

Tasa de crecimiento de los beneficios

15.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals 6.0%
Tasa de crecimiento de los ingresos-100.0%
Rentabilidad financiera-299.9%
Margen neton/a
Última actualización de beneficios31 Dec 2022

Actualizaciones de resultados anteriores recientes

No hay actualizaciones

Recent updates

Vallon Pharmaceuticals reports Q2 results

Jul 28

We're Keeping An Eye On Vallon Pharmaceuticals' (NASDAQ:VLON) Cash Burn Rate

Dec 15
We're Keeping An Eye On Vallon Pharmaceuticals' (NASDAQ:VLON) Cash Burn Rate

We Think Vallon Pharmaceuticals (NASDAQ:VLON) Needs To Drive Business Growth Carefully

Aug 17
We Think Vallon Pharmaceuticals (NASDAQ:VLON) Needs To Drive Business Growth Carefully

Will Vallon Pharmaceuticals (NASDAQ:VLON) Spend Its Cash Wisely?

May 17
Will Vallon Pharmaceuticals (NASDAQ:VLON) Spend Its Cash Wisely?

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Vallon Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NasdaqCM:VLON Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 220-761
30 Sep 220-954
30 Jun 220-954
31 Mar 220-955
31 Dec 210-945
30 Sep 210-834
30 Jun 210-725
31 Mar 210-625
31 Dec 200-514
30 Sep 200-413
30 Jun 200-413
31 Mar 200-412
31 Dec 190-312

Ingresos de calidad: VLON is currently unprofitable.

Margen de beneficios creciente: VLON is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: VLON is unprofitable, and losses have increased over the past 5 years at a rate of 25.1% per year.

Acelerando crecimiento: Unable to compare VLON's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: VLON is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.6%).


Rentabilidad financiera

Alta ROE: VLON has a negative Return on Equity (-299.91%), as it is currently unprofitable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado